Abstract
Approximately a quarter of the Non-small Cell Lung Cancer (NSCLC) patients with a locally advanced disease. This stage includes heterogeneous diseases in terms of initial clinical presentation and of histology. An optimal initial staging integrating a PET/CT and an injected brain imaging is necessary. Pulmonary function test is to be systematically realized when surgery is possible but also before radiotherapy. The therapeutic strategy is decided in a multidisciplinary board within an experienced team. Surgery is a possible option but generally preceded by a neo-adjuvant treatment. Most of NSCLC stage IIIB and IIIC patients receive a radiochemotherapy, a concomitant strategy is to be favored to a sequential one. Chemotherapy is based on platinum doublet should be started as early as possible. For the patients who could not benefit from concomitant chemotherapy a sequential normofractionnated or hypofractionnated radiotherapy, or even chemotherapy alone are possible alternatives to be discussed. A consolidation systemic treatment after radiochemotherapy by durvalumab, an anti-PD-L1 checkpoint immunotherapy will become probably a standard on the basis of the outcomes of the PACIFIC trial.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
